Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 12/20 | 0.58 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.51 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL62132 | 1.00 | VNN1 (0.58) | VNN1ADRB2ADRB1ADRB3PTGS1 | |
| SCHEMBL14548305 | 0.91 | ADRB2 (0.51) | VNN1ADRB2ADRB1ADRB3CYP2D6 | |
| SCHEMBL2076013 | 0.86 | EPHX2 (0.54) | VNN1KMT2APOLB | |
| SCHEMBL10875319 | 0.85 | VNN1 (0.62) | VNN1PTGS1KCNH2CYP2D6CYP2C19 | |
| SCHEMBL17742177 | 0.83 | VNN1 (0.65) | VNN1ADRB2PTGS1KCNH2 | |
| SCHEMBL8417457 | 0.81 | VNN1 (0.68) | VNN1PTGS1KCNH2CYP2D6CYP2C9 | |
| SCHEMBL17742145 | 0.81 | VNN1 (0.65) | VNN1PTGS1KCNH2CYP2D6CYP2C9 | |
| SCHEMBL8417455 | 0.81 | VNN1 (0.68) | VNN1PTGS1KCNH2CYP2D6CYP2C9 | |
| SCHEMBL15799945 | 0.80 | PTGS1 (0.60) | VNN1PTGS1KCNH2 | |
| SCHEMBL17061585 | 0.79 | VNN1 (0.62) | VNN1PTGS1KCNH2CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129562-B2 | Carboxylic acid derivatives | DSM IP ASSETS B.V. (NL) | 2012-03-06 | — | — | US | disclosed |
| US-20110124726-A1 | NOVEL CARBOXYLIC ACID DERIVATIVES | DSM IP ASSETS B.V. | 2011-05-26 | — | — | US | disclosed |
| US-7906496-B2 | Carboxylic acid derivatives | DSM IP ASSETS B.V. (NL) | 2011-03-15 | — | — | US | disclosed |
| US-7906496-B2 | Carboxylic acid derivatives | DSM IP ASSETS B.V. (NL) | 2011-03-15 | — | — | US | disclosed |
| US-20090258887-A1 | Novel Carboxylic Acid Derivatives | DSM ASSETS B.V. (NL) | 2009-10-15 | — | — | US | disclosed |
| US-20090258887-A1 | Novel Carboxylic Acid Derivatives | DSM ASSETS B.V. (NL) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258887-A1 | Novel Carboxylic Acid Derivatives | AADAC, ALDH7A1, DDC | VNN1 1700/4885ADRB2 4145/4885ADRB1 3839/4885 |
| US-20110124726-A1 | NOVEL CARBOXYLIC ACID DERIVATIVES | AADAC, ALDH7A1, ALDH18A1 | VNN1 1644/4885ADRB2 4179/4885ADRB1 3899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.